NEA Secondary — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)Kanya Rajangam(President, Head of Research & Development and Chief Medical Officer)Yvonne Li(Executive Officer)James Collins(Director)
BoardDonald Tang(Director)
Board seatEdward Mathers· per SEC Form D · $40M raise · filed Jun 2026
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNSG Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.